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Abstract
Background: Osteosarcoma predominantly afflicts young people in their second and third decades of life. When
osteosarcoma arises in patients older than 40 years, the prognosis is usually poorer compared to their younger
counterparts. Although the clinical, histopathologic features and prognostic indicators are well defined for young
patients, much less is known about affected adults. The purpose of this study is to describe our institution's
experience with the management of osteosarcoma in patients greater than 40 years and also evaluate, by
immunohistochemical analysis, the prognostic significance of microvessel density, as a marker of intratumoural
angiogenesis.
Methods: A retrospective clinicopathological analysis was performed on 11 patients over the age of 40 years
that were treated at our institution between 1996 and 2004. Archival pre-treatment biopsy tissue was retrieved
for immunohistochemical staining against two endothelial cell markers (CD31 and CD34) and also against VEGF.
Angiogenesis was assessed by determining the intratumoural microvessel density (MVD) and the degree of VEGF
expression in these specimens. This was correlated with patient outcome in terms of local recurrence, metastasis
and death. Histological results were also compared to a group of patients less than 40 years of age.
Results: Of the 11 patients, 9 were male and 2 were female and the mean age was 58 years (range, 42–85). In 7
patients, osteosarcoma arose secondarily from Paget's disease of the bone. The most common site involved was
the humerus (7) followed by the femur (2) then pelvis (1) and ulna (1). At the time of diagnosis, 4 patients had
metastatic disease. Preoperative chemotherapy was given to 4 patients, with a good response in 3 patients. Six
patients underwent limb-sparing surgery, 4 had amputations and 1 was treated with radiotherapy alone. The mean
follow up time was 31.5 months (range, 8–81). At this time, 4 patients (36%) had developed lung metastases and
5 patients (46%) had died. Overall survival was 54.5%. Intratumoural MVD was higher in patients over 40 years,
although not statistically significant (p = 0.111, CD31; p = 0.134, CD34). VEGF was uniformly expressed in all
sections, however no relationship was found between the degree of expression and patient age.
Conclusion:  The prognosis for older patients with osteosarcoma is generally poor. Initial presentation is
commonly associated with metastatic disease and neoadjuvant chemotherapy is often avoided because of its side
effects. Increased intratumoural vascularity may contribute to the poorer prognosis in these patients, however
further studies are needed.
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Introduction
Osteosarcoma is the commonest primary tumour that
arises from bone and is the second highest cause of can-
cer-related death in the paediatric age group. It most com-
monly afflicts young people in the second and early third
decades of life, with over 60% of diagnoses being made
between the ages of 10–20 years. However, when osteosa-
rcoma occurs in patients older than the age of 40 years, it
is usually in the setting of a pre-existing condition such as
Paget's disease or prior irradiated bone and occasionally
in osteogenesis imperfecta [1,2]. The prognosis in older
patients is notoriously poorer compared to children and
adolescents, and several studies have shown that progno-
sis worsens with age among adults, but is age-independ-
ent in children [3]. This is largely attributable to an
inability to tolerate high dose chemotherapy, and a ten-
dency towards non-extremity tumour sites [4]. Although
the clinical, histopathologic features and prognostic indi-
cators are well defined for young patients, much less is
known about affected adults.
Modern treatment of osteosarcoma aims at effectively
inhibiting tumour growth, therefore permitting safe
tumour resection and subsequent reconstruction of the
limb, and prevention of metastatic disease. To achieve
this, aggressive and intense cure-oriented combined
modality chemotherapy has been developed over the last
2–3 decades. The most commonly used regime comprises
of doxorubicin, cisplatin, ifosfamide and high-dose meth-
otrexate. Although there has been a significant improve-
ment in long-term outcome in these patients, 25–50% of
patients subsequently develop metastatic disease, and this
remains the major cause of death [5]. Furthermore, this
form of treatment is often associated with significant mor-
bidity and therefore only justified in younger patients.
In recent times, much research focus has been directed at
the role of angiogenesis in tumour development, growth,
invasion and metastasis. Angiogenesis, which is most
commonly assessed by intratumoural microvessel density
(MVD), is the formation of new blood vessels from pre-
existing ones, and has shown to correlate with clinico-
pathological factors and patient prognosis in a variety of
tumours including breast, prostate and gastric carcinomas
[6-9]. Moreover, it is becoming increasingly clear that
tumour angiogenesis is the result of an imbalance
between pro-angiogenic and ant-angiogenic factors, and
induction of the "angiogenic switch" leads to a threshold
change in the favour of pro-angiogenesis [10]. While ang-
iogenic inhibitors have been used increasingly in a
number of clinical trials for the treatment of advanced
cancers, their potential role as an adjuvant to chemother-
apy in osteosarcoma, a hypervascular tumour, is still
unclear. Few studies have been performed, reporting var-
ying results and conflicting conclusions. While Mikulic et
al  (2004) showed poorer prognosis in osteosarcoma
patients with increased MVD, Matadakis et al (2001)
failed to demonstrate any association with MVD and out-
come [11,12]. On the other hand, Kreuter et al (2004)
reported that increased angiogenesis is a prognostic indi-
cator for higher survival and favourable response rates to
chemotherapy [13].
It is in theory that by targeting tumour endothelial cells or
inhibiting certain angiogenic factors, such as VEGF, this
may be an effective way of controlling tumour growth
with increased specificity and less systemic toxicity.
Hence, the purpose of this study was to describe our insti-
tution's experience with the management of osteosar-
coma in patients over the age of 40 years and also to
determine the role of angiogenesis, as a prognostic factor,
in these patients.
Materials and methods
Patients and tissue specimens
The Bone and Soft Tissue Tumour Service at St. Vincent's
Hospital and Peter MacCallum Cancer Institute, Mel-
bourne is an adult tertiary referral centre for the manage-
ment of musculoskeletal tumour patients in Victoria and
Tasmania, Australia and services a population of approxi-
mately 4 million people. A retrospective analysis was per-
formed identifying all patients with osteosarcoma that
were treated at our institution by the senior author
(PFMC) between 1996 and 2004. In order to be eligible
for this study, patients had to have presented with newly
diagnosed osteosarcoma (either primary or secondary)
and had not received neoadjuvant chemotherapy or radi-
otherapy prior to diagnostic biopsy.
During the study period of 8 years, 46 patients were diag-
nosed with osteosarcoma at the authors' institution, of
which, 11 were over the age of 40 years (24%). An analysis
of those patient over the age of 40 years was performed
and the following variables were evaluated: age, sex, pres-
entation, clinical course and subsequent treatment,
tumour histology, site, response to chemotherapy, the
development of metastases and long term survival.
Tumours were classified according to predominant histo-
logic features.
In order to evaluate the degree of tumour angiogenesis in
this group, archival paraffin-embedded tissue of the pre-
treatment diagnostic biopsies were retrieved from our
institution's pathology department. Of the 11 patients,
there were only 8 cases where sufficient archival paraffin-
embedded tissue were available for histological and
immunohistochemical analysis. The degree of angiogen-
esis was then compared to a group of 17 patients with
osteosarcoma that were below the age of 40 years.International Seminars in Surgical Oncology 2006, 3:7 http://www.issoonline.com/content/3/1/7
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Immunohistochemical staining for CD 31, CD34 and VEGF
Archival formalin-fixed paraffin-embedded blocks of the
diagnostic core biopsy tissue were retrieved and immuno-
histochemical staining was performed on 5 µm serial sec-
tions. In order to visualise the microvessels,
immunostaining was performed using 2 well-known
endothelial cell markers, CD31 and CD34. A monoclonal
mouse-anti-human antibody to CD31 (DakoCytomation,
Glostrup, Denmark) at 1:20 dilution and a monoclonal
mouse-anti-human antibody to CD34 (DakoCytomation,
Glostrup, Denmark) at 1:25 dilution were used. Immu-
nolocalisation of VEGF was performed using a rabbit pol-
yclonal IgG antibody at 1:100 dilution (Santa Cruz
Biotechnology, Santa Cruz, CA). Standard indirect immu-
nohistochemisty was performed using the avidin-biotin-
peroxidase complex technique, with minor modifica-
tions. Briefly, after deparaffinizing the sections in Solv21
(United Biosciences, QLD, Australia) and rehydrating the
tissue sequentially through ethanol, antigen retrieval was
performed by microwave heating with 10 mM Tris, 1 mM
EDTA (pH 9.0) buffer solution for 12 minutes. Sections
were treated for 30 minutes with 10% hydrogen peroxide
in dH2O to block endogenous peroxidase activity. Subse-
quently, the tissue was immersed in 10% normal rabbit
serum for 30 minutes, and then incubated with the pri-
mary antibody overnight at 4°C. After two washes in 1×
PBS, a biotinylated rabbit-anti-mouse secondary antibody
was applied for the CD31 and CD34 stained sections and
a biotinylated goat-anti-rabbit secondary antibody
(DakoCytomation, Glostrup, Denmark) was applied for
the VEGF stained sections (1:300 dilution for 30 min-
utes). Following this, the slides were washed again in 1×
PBS and then treated with peroxidase-conjugated strepta-
vidin for 20 minutes, and the specific antibody binding
was visualised using 3,3'-diaminobenzidine tetrahydro-
chloride (DAB). Specificity of immunoreactivity was con-
firmed by substitution of the primary antibody with PBS,
and in all negative controls, no staining was observed.
Light counterstaining with Harris haematoxylin was per-
formed.
Assessment of intra-tumoural microvessel density (MVD)
The degree of intratumoural angiogenesis was determined
by calculating the microvessel density (MVD). Immuno-
histochemical assessment was performed using light
microscopy and the MVD was assessed according to the
International Consensus Report, by two independent
investigators, who were blinded to the diagnosis, clinical
course, management and outcome of the patients [14].
Briefly, the entire section was systematically scanned at
100× magnification and the areas of most intense vascu-
larisation, ie. greatest number of CD31 or CD34-antigen
positive cells, was classified as a "hot spot". In order to be
defined as a "hot spot", the density of antigen-positive
cells and cell clusters need to greater relative to adjacent
areas. A positive vessel is a single endothelial cell,
endothelial cell cluster, or microvessel that is clearly sepa-
rated from adjacent microvessels [7]. The magnification
was changed to 200× then 400×, and the slide was reposi-
tioned over the area of the "hot spot" with the most ves-
sels per field. For each section, the 3 "hottest" spots were
assessed and the mean count of all independent readings
is calculated and the mean count is defined as the mean
count of microvessels per 400× field area (0.26 mm2). The
MVD was assessed using CD31 and CD34 counts sepa-
rately.
Assessment of VEGF expression
Semiquantitative assessment of VEGF expression was
made at 200× magnification, based on the overall inten-
Table 1: Patient and tumour characteristics
Features No.
Gender
Male 9 (81.8%)
Female 2 (18.2%)
Median Age (range) 58.3 (42–85)
Tumour site
Humerus 7 (63.6%)
Femur 2 (18.2%)
Pelvis 1 (9.1%)
Ulna (proximal) 1 (9.1%)
Primary or Secondary osteosarcoma
Primary 4 (36.4%)
Secondary – Paget's Disease 7 (63.6%)
Primary metastases
Absent 7 (63.6%)
Present 4 (36.4%)
Histological subtype
Osteoblastic 11 (100%)International Seminars in Surgical Oncology 2006, 3:7 http://www.issoonline.com/content/3/1/7
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(A) T2-weighted and (B) T1-weighted coronal magnetic resonance images (MRI) of a 43 year old man presenting with oste- osarcoma involving the proximal humerus (arrows) Figure 1
(A) T2-weighted and (B) T1-weighted coronal magnetic resonance images (MRI) of a 43 year old man presenting with oste-
osarcoma involving the proximal humerus (arrows). (C) Antero-posterior and (D) lateral post-operative plain radiographs 
demonstrating the surgical management, which comprised of a proximal humeral resection and a claviculo-prohumeral recon-
struction of the shoulder.International Seminars in Surgical Oncology 2006, 3:7 http://www.issoonline.com/content/3/1/7
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45 year old man with osteosarcoma involving his humerus Figure 2
45 year old man with osteosarcoma involving his humerus. (A) Coronal T1-weighted MRI demonstrating the tumour involving 
the proximal half of the humerus. (B) Bone scan demonstrates increased uptake in the area of the tumour on the delayed 
static image. (C) and (D) Subsequent operative management comprised of a total humeral resection and endoprosthetic 
reconstruction.
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(A) Plain lateral radiograph showing the characteristic ill-defined lesion with both lytic and osteoblastic features and evidence  of periosteal elevation (Codman's triangle) (arrow) Figure 3
(A) Plain lateral radiograph showing the characteristic ill-defined lesion with both lytic and osteoblastic features and evidence 
of periosteal elevation (Codman's triangle) (arrow). (B) T1-weighted magnetic resonance image showing the intramedullary 
extension of the tumour, with cortical destruction and extension into the soft tissue. (C) Lateral and (D) anteroposterior 
plain radiographs post distal femoral resection and reconstruction of the knee joint with a GMRS (Global modular replacement 
system, Stryker Howedica) megaprosthesis.
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sity of membranous and cytoplasmic staining within the
tumour cells and the percentage of cells stained. Four
grades were given – negative, low (+), moderate (++), and
strong (+++). Variations in grading between the two
observers were identified and the cases were individually
discussed and a final consensus was made.
Statistical analysis
Results were analysed using MedCalc for Windows v8.1
(Medcalc Software, Belgium). Non-parametric tests were
used to allow for data that was not normally distributed.
Associations between age and MVD or the degree of VEGF
expression were analysed using the Mann-Whitney U test.
Correlation between MVD or VEGF expression and
patient age was determined using Spearman's Rank co-
efficient. A p-value ≤ 0.05 was considered significant.
Results
Patient and tumour characteristics
Eleven patients above the age of 40 years with osteosar-
coma were treated at our institution between 1996 and
2004 (Table 1). The mean age was 58.3 years (range, 42–
85 years). Nine patients were male and 2 were female. At
the time of presentation, 7 patients had apparent localised
disease and 4 had evidence of metastatic disease; 2 had
lung metastases, 1 had a subcutaneous metastasis to the
calf and 1 had a bony metastasis to the tibia. Osteosar-
coma arose secondarily to Paget's disease of the bone in 7
patients. Seven of the tumours were located in the
humerus, 2 in the femur, 1 in the proximal ulna, and 1 in
the pelvis. No patients presented with pathological frac-
ture.
In terms of histologic subtype, all 11 osteosarcoma were
classified as high-grade osteoblastic lesions. Estimates of
tumour volume were available in 8 of the 10 patients who
subsequently had surgical resection. Tumour volume was
calculated as length × width × depth × 0.52 cm3, and the
mean value was 338.3 cm3 (range, 55.9–709.3 cm3).
(A) and (B) Anteroposterior and lateral plain radiographs displaying typical pagetoid changes to the proximal femur with evi- dence of tumour extending beyond the cortex into the soft tissue (arrows) Figure 4
(A) and (B) Anteroposterior and lateral plain radiographs displaying typical pagetoid changes to the proximal femur with evi-
dence of tumour extending beyond the cortex into the soft tissue (arrows). This 85 year old lady was managed conservative 
with radiotherapy alone.International Seminars in Surgical Oncology 2006, 3:7 http://www.issoonline.com/content/3/1/7
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(A) CD31 and (B) CD34 immunostaining demonstrating the intratumoural microvessels (arrows) Figure 5
(A) CD31 and (B) CD34 immunostaining demonstrating the intratumoural microvessels (arrows). Magnification 200×.International Seminars in Surgical Oncology 2006, 3:7 http://www.issoonline.com/content/3/1/7
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Photomicrographs demonstrating immunohistochemical staining of osteosarcoma tissue for VEGF Figure 6
Photomicrographs demonstrating immunohistochemical staining of osteosarcoma tissue for VEGF. Panels (A) and (B) are a 
200× and 400×, respectively.International Seminars in Surgical Oncology 2006, 3:7 http://www.issoonline.com/content/3/1/7
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Treatment and clinical outcomes
Ten of the 11 patients underwent surgical resection of the
tumours. Of the 10 patients, 4 had limb amputations (two
above elbow, one above knee and one forequarter ampu-
tation) and 6 had limb-sparing surgery. For the 4 humeral
lesions, reconstructive procedures comprised of 1 resec-
tion of the proximal humerus and claviculo-prohumeral
reconstruction, 1 allograft replacement and arthrodesis of
the proximal humerus, 1 proximal humeral replacement
and 1 total humeral replacement (Figures 1, 2). The pelvic
osteosarcoma was treated with an internal hemipelvec-
tomy and reconstruction with a saddle prosthesis arthro-
plasty (Link, Exactech, Florida, USA) to restore a mobile
hip joint. One patient had a distal femoral resection and
reconstruction of the knee with a Global Modular
Replacement System (GMRS, Stryker Howmedica) (Figure
3). One patient received only external beam radiotherapy
to the tumour as a form of local palliative control (Figure
4). Adequate margins were achieved in all cases at the
time of surgery.
Four patients received both neoadjuvant and adjuvant
chemotherapy. The treatment regimes comprised of a
combination of standard agents and were administered
according to current protocols. These included doxoru-
bicin (n = 4), cisplatin (n = 3), Ifosfamide (n = 1) and high
dose methotrexate (n = 1). In terms of histological
response, 3 (75%) had a good response (≥ 90% necrosis),
and 1 (25%) had a poor response (<90% necrosis). One
patient received adjuvant chemotherapy alone and one
had a combination of adjuvant chemotherapy and radio-
therapy to the lesion. In all cases, the chemotherapy was
relatively well tolerated, with no notable toxicity-related
complication.
The mean follow up period was 31.5 months (range, 8–81
months). At the time of latest review, 5 patients (46%)
had died of their disease. Four patients were continuously
disease-free and 2 patients were disease-free after pulmo-
nary metastasectomy. The overall survival was 54.5%.
During the time of the study, no patients had developed a
local recurrence. Of the 7 patients that were metastasis-
free at initial diagnosis, 4 (57%) went on to develop met-
achronous lesions in the lung at a mean time of 13
months (range, 1–24 months). The management in 3
patients comprised of pulmonary metastasectomy. For
the 4 patients that received neo/adjuvant chemotherapy,
only 2 (50%) were continuously disease-free at the time of
latest follow up (mean, 36 months).
Assessment of angiogenesis and its correlation with patient 
age
Intratumoural MVD and the level of VEGF expression was
compared between two groups: patients above and below
the age of 40 years. The mean age of the patients over 40
years (n = 8) was 56.1 years (range, 42–85 years), while
those less than 40 years (n = 17) was 21.6 years (range,
13–36 years).
For the patients older than 40 years, the median MVD
from CD31 immunostaining was 37 microvessels per
0.26 mm2 (interquartile range of 23 to 49). From CD34
expression, the median MVD was 52 microvessels per
0.26mm2 (interquartile range of 32 to 60). In the group of
patients less than 40 years, the median MVD from CD31
immunostaining was 22 microvessels per 0.26 mm2
(interquartile range of 18 to 30). The median MVD from
CD34 expression was 29 microvessels per 0.26 mm2
(interquartile range of 23 to 46) (Figure 5). From these
results, for both CD31 and CD34, the median MVD was
higher in the older group of patients. However, although
this did not demonstrate any statistically significant differ-
ence (p = 0.111, CD31; p = 0.134, CD34), there is evidence
that a trend may exist to suggest that patients over the age
of 40 years have a higher MVD compared to those less
than 40 years.
In terms of VEGF expression, all of the 25 tumour speci-
mens showed positive cytoplasmic VEGF protein expres-
sion in the tumour cells (Figure 6). Superficial
examination of the specimens at 100× magnification
revealed apparent localised variation in the expression of
VEGF protein, with areas of negative expression inter-
spersed throughout the sections. In the great majority of
cases, this corresponded to areas of increased microvessels
density ("hot spots") as determined by CD31 and CD34
VEGF staining intensity according to patient age Figure 7
VEGF staining intensity according to patient age. No 
statistical correlation was found between the degree of 
VEGF staining and increasing patient age. The dotted line 
delineates patients above and below the age of 40 years. No 
statistical difference was noted between the two groups.
VEGF Expression vs Age
0
1
2
3
5 2 54 56 58 5
Age
G
r
a
d
e
40 yo
(r = -0.229, p = 0.27) International Seminars in Surgical Oncology 2006, 3:7 http://www.issoonline.com/content/3/1/7
Page 11 of 12
(page number not for citation purposes)
immunostaining. However, there was no significant dif-
ference observed between the two groups (p = 0.66). Fur-
thermore, no correlation was seen between the degree of
VEGF expression and increasing patient age (r = -0.229, p
= 0.27) (Figure 7). No significant correlation was demon-
strated in the MVD and VEGF expression between patients
with primary and secondary (Paget's disease) osteosar-
coma. Moreover, in patients who had received neo/adju-
vant chemotherapy, no statistical significance was noted
between VEGF staining, patient gender, the development
of recurrence, metastasis or death.
Discussion
The incidence of osteosarcoma has a well-recognised dou-
ble peak. Although, the majority of tumours arise in
patients in their adolescence, there is a significant second
peak in the later years of life, with approximately 13% of
patients being over the age of 40 years [15]. Most studies
have concluded that patients over the age of 40 years fare
considerably worse compared to their younger counter-
parts, which may be attributable to their potential inabil-
ity to tolerate aggressive chemotherapeutic agents and
also a tendency towards non-extremity tumour sites [16].
The prognostic significance, however of age in osteosar-
coma is generally difficult to assess, as in most clinical tri-
als and multivariate analyses, older patients are excluded.
Although Bacci et al reported that the overall survival in 29
patients over the age of 40 years was not worse than
patients under 40 years, Naka et al showed a dismal 18%
5-year survival rate for 12 patients and Carsi et al pub-
lished a 42% overall survival rate [3,16,19]. This disparity
in outcome is in the context that since the advent of multi-
modal high dose chemotherapy as an adjunct to the sur-
gical management of osteosarcoma, the long-term sur-
vival for osteosarcoma, across all ages, has risen to
approximately 70% [4]. In this present study, we
attempted to determine by immunohistochemistry,
whether increased microvessel density or the expression
of pro-angiogenic factors, such as VEGF, in older patients
might be an attributable factor in the poorer prognosis in
this age group.
The concept that malignant tumour development,
growth, invasion and metastasis depends on angiogenesis
is now a widely recognised and accepted theory. Several
clinical studies on various types of malignant tumours
have supported this demonstrating a positive correlation
between intratumoural microvessel density and certain
clinicopathological factors and patient prognosis [6].
Tumour angiogenesis is a result of an imbalance between
pro-angiogenic and anti-angiogenic factors [20]. Folkman
postulated that dormant avascular tumour nodules could
only grow and develop if they became vascularized. There-
fore, the induction of the "angiogenic switch" on
tumours, to develop an angiogenic phenotype is key proc-
ess in malignant invasion and metastasis [21,22]. Thus,
there is a threshold change in the balance between stimu-
latory and inhibitory influences, in favour of pro-angio-
genesis. In recent times, much research focus has been
directed towards investigating whether interruption of
this process could theoretically halt the progression of
tumours that are dependent on angiogenesis for further
growth. This therapeutic potential could augment the
effects of chemotherapy and radiotherapy by limiting the
tumour to a dormant state of low metastatic potential
[23].
VEGF is one of the most potent known stimulators of ang-
iogenesis and acts by activating endothelial cells via inter-
action with its receptors, Flk-1 and Flt-1, which are
selectively expressed in the endothelium [24]. The impor-
tant role of VEGF in tumour metastasis has been demon-
strated by positive correlation between VEGF expression
and the development of metastatic disease and overall
prognosis in gastric, colorectal and oesophageal carci-
noma [25-27]. This association is further echoed in oste-
osarcoma with positive VEGF expression correlating with
increased local microvessel density, development of pul-
monary metastasis and poor outcome [28].
In our study, we did not observe any significant correla-
tion between the grade of VEGF immunostaining and
patient age. Furthermore, the degree VEGF expression did
not seem to be associated with other clinicopathological
parameters such as the development of local recurrence,
metastasis and death. In our observation of 25 cases, pos-
itive VEGF expression was demonstrated in all tumour
"hot spots", which may be an expected finding consider-
ing VEGF is a potent pro-angiogenic factor. However, the
premise of assessing the degree of VEGF protein expres-
sion was to determine whether there was variation in ang-
iogenic factor regulation between different tumours, and
in turn, whether this had any relationship to tumour pro-
gression. Therefore, although the degree of expression
may not provide prognostic significance, it is likely to be
of key functional importance, as it is uniformly expressed
in all tumour samples.
Conclusion
In this present study, the aims were two-fold; firstly to
describe our institution's experience with the manage-
ment of osteosarcoma in older patients, and secondly to
determine whether there was any correlation between the
intratumoural microvessel density or the degree of pro-
angiogenic factor expression (VEGF) and patient age. The
results of this study have demonstrated that the intratu-
moural microvessel density was higher in patients over
the age of 40 years, and although this was not statistically
significant, there may be suggestion that a trend may exist.
Furthermore, VEGF was uniformly expressed in all oste-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
International Seminars in Surgical Oncology 2006, 3:7 http://www.issoonline.com/content/3/1/7
Page 12 of 12
(page number not for citation purposes)
osarcoma specimens, however no significant relationship
was found between the degree of VEGF staining and
patient age. We do appreciate that this is a small series,
however we have observed that the overall survival is
poorer in older patients, and this is consistent with cur-
rent literature. This may be attributed to increased intratu-
moural vascularity, however further studies need to be
performed. If this is the case, there may be a potential role
for anti-angiogenic therapy, as an augment to chemother-
apy, for these more elderly patients with osteosarcoma.
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